Malignant growth leads to an unremitting increase in tumor burden despite treatment with antineoplastic agents. Treatment advances have been largely empirical, with improvements in surgical technique and the delivery of radiation therapy, leading to combined modality therapies that have improved outcomes for many patients. Loss of normal growth regulatory mechanisms and infinite replicative capacity are common features of many human malignancies. Successful targeting of the process whereby malignant cells become or maintain an immortal state should be an effective strategy for a number of cancers. Telomerase inhibition represents a new paradigm for, the treatment of human malignancies. As stated in Specific Aim 3, we will select and characterize human tumor cell lines and pathologic tumor samples from patients with representative tumor types of different stages for telomerase activity and telomere length.
In Specific Aim 6, an in vitro evaluation of compounds identified in the high throughput screen will be examined against normal, tumor, and leukemia cell lines representative of the clinical profile studied in Specific Aim 3 to complement in vitro studies that will be conducted at Geron. Specifically, experiments will be conducted using cell lines and cultured primary tumors to examine the effects of a telomerase inhibitor on growth kinetics, telomerase activity, and telomere length.
In Specific Aim 7 an assay will be developed for the detection of a candidate telomerase inhibitor(s) in biological materials. Pharmacology, drug metabolism, and pharmacokinetic studies will be conducted in order to optimize the bioavailability and activity of the compound in anticipation of performing animal experiments.
In Specific Aim 8 we will select compounds showing in vitro efficacy and evaluate their effects on normal, and immunocompromised mice transplanted with tumor cell lines, primary tumors, or leukemias. Dosing schedules will be optimized and different routes of administration (p.o., i.v,, i.p., s.c.) will be evaluated. The capacity of telomerase inhibitors to block the development of tumors, to regress established tumors with or without chemotherapy, and/or to prevent metastasis will be measured. Quantitative measurements of tumor burden and residual disease will be determined by sensitive serologic, fluorescence, chromophilic, or molecular techniques. Telomerase levels and telomere length will be measured in control and treated tumors as a function of growth rate and time.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Geron Corporation
Menlo Park
United States
Zip Code
Gammaitoni, Loretta; Weisel, Katja C; Gunetti, Monica et al. (2004) Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood 103:4440-8
Wang, Eunice S; Wu, Kaida; Chin, Allison C et al. (2004) Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103:258-66
Asai, Akira; Oshima, Yuko; Yamamoto, Yoshihiro et al. (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63:3931-9
Franco, S; Ozkaynak, M F; Sandoval, C et al. (2003) Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 17:401-10
Wu, Kai-Da; Orme, Lisa M; Shaughnessy Jr, John et al. (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101:4982-9
Boklan, Jessica; Nanjangud, Gouri; MacKenzie, Karen L et al. (2002) Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res 62:2104-14
Franco, S; MacKenzie, K L; Dias, S et al. (2001) Clonal variation in phenotype and life span of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT). Exp Cell Res 268:14-25
Engelhardt, M; Mackenzie, K; Drullinsky, P et al. (2000) Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 60:610-7
Albanell, J; Bosl, G J; Reuter, V E et al. (1999) Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst 91:1321-6
Engelhardt, M; Ozkaynak, M F; Drullinsky, P et al. (1998) Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 12:13-24

Showing the most recent 10 out of 17 publications